Bavarian Nordic A/S (OTCMKTS:BVNRY – Get Rating) was the recipient of a large drop in short interest in August. As of August 31st, there was short interest totalling 21,100 shares, a drop of 11.3% from the August 15th total of 23,800 shares. Based on an average daily trading volume, of 503,900 shares, the days-to-cover ratio is currently 0.0 days.
Analyst Upgrades and Downgrades
Separately, Cowen upgraded shares of Bavarian Nordic A/S from a “market perform” rating to an “outperform” rating in a research report on Wednesday, July 20th.
Bavarian Nordic A/S Stock Down 4.2 %
Shares of OTCMKTS:BVNRY opened at $9.95 on Monday. The stock has a market cap of $2.10 billion, a PE ratio of -20.73 and a beta of 1.49. The company’s fifty day moving average is $14.04 and its 200 day moving average is $10.66. Bavarian Nordic A/S has a 52 week low of $5.85 and a 52 week high of $19.31.
About Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.
- Get a free copy of the StockNews.com research report on Bavarian Nordic A/S (BVNRY)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
Receive News & Ratings for Bavarian Nordic A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic A/S and related companies with MarketBeat.com's FREE daily email newsletter.